adal-1 Antibody

What is ADAL-1 antibody and what protein does it target?

ADAL-1 antibody is designed to detect the adenosine deaminase-like protein (ADAL), a member of the Adenosine and AMP deaminases protein family. In humans, the canonical ADAL protein comprises 355 amino acid residues with a molecular mass of approximately 40.3 kDa . This antibody specifically recognizes epitopes on the ADAL protein, which functions as a catalyst in the hydrolysis of free cytosolic methylated adenosine nucleotide N(6)-methyl-AMP (N6-mAMP) to produce inositol monophosphate (IMP) and methylamine . The specificity of recognition depends on the antibody's design, with some versions targeting the C-terminal region, particularly amino acids 317-344 .

How is ADAL-1 antibody structurally organized and what are its binding characteristics?

ADAL-1 antibody is typically generated from rabbits immunized with a KLH-conjugated synthetic peptide corresponding to amino acids 317-344 from the C-terminal region of human ADAL protein . The antibody is commonly purified using Protein A affinity chromatography, which ensures high specificity for the target antigen . The binding domain is configured to recognize specific epitopes on the ADAL protein with high affinity, allowing for sensitive detection in various experimental applications. The antibody's structure incorporates variable regions that determine its specificity and constant regions that dictate its functional properties within experimental systems.

What is the cross-reactivity profile of ADAL-1 antibody across different species?

The ADAL-1 antibody demonstrates cross-reactivity with ADAL proteins from multiple species, making it versatile for comparative studies. Based on available data, this antibody has confirmed reactivity with human and mouse ADAL proteins . Additional cross-reactivity has been reported with ADAL from rat, bovine, dog, guinea pig, horse, pig, zebrafish, and several other vertebrate species . This broad cross-reactivity profile stems from the high conservation of ADAL protein sequences across vertebrate species, particularly in the C-terminal region where many ADAL antibodies, including ADAL-1, bind.

What are the validated applications for ADAL-1 antibody in laboratory research?

ADAL-1 antibody has been validated for multiple experimental applications in laboratory research. Western blotting (WB) serves as the primary application, where the antibody effectively detects ADAL protein in denatured samples . Immunohistochemistry (IHC), including paraffin-embedded section staining (IHC-P), represents another validated application allowing visualization of ADAL distribution in tissue samples . The antibody is also suitable for enzyme-linked immunosorbent assay (ELISA) analysis, enabling quantitative measurement of ADAL protein in complex samples . Each application requires specific optimization parameters to ensure reliable and reproducible results when using ADAL-1 antibody.

What is the recommended protocol for Western blot analysis using ADAL-1 antibody?

For optimal Western blot results with ADAL-1 antibody, researchers should follow this methodological approach:

• Sample preparation: Prepare protein lysates from tissues or cells of interest using a standard lysis buffer containing protease inhibitors.

• Protein separation: Separate 20-50 μg of total protein on a 10-12% SDS-PAGE gel.

• Transfer: Transfer proteins to a PVDF or nitrocellulose membrane at 100V for 60-90 minutes.

• Blocking: Block non-specific binding sites with 5% non-fat dry milk or 3% BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute ADAL-1 antibody at 1:500 to 1:2000 in blocking buffer and incubate the membrane overnight at 4°C.

• Washing: Wash membrane 3-5 times with TBST, 5 minutes each.

• Secondary antibody: Incubate with HRP-conjugated or other labeled secondary antibody (species-specific to the ADAL-1 host) for 1-2 hours at room temperature.

• Detection: Develop using chemiluminescent substrate and image using appropriate documentation system.

Researchers should expect to observe a specific band at approximately 40-42 kDa corresponding to ADAL protein .

How should ADAL-1 antibody be optimized for immunohistochemistry applications?

For effective immunohistochemistry using ADAL-1 antibody, researchers should:

• Tissue preparation: Fix tissues in 10% neutral buffered formalin and embed in paraffin.

• Sectioning: Cut 4-6 μm sections and mount on positively charged slides.

• Deparaffinization: Remove paraffin and rehydrate through graded alcohols to water.

• Antigen retrieval: Perform heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes.

• Endogenous peroxidase blocking: Block with 3% hydrogen peroxide for 10 minutes.

• Protein blocking: Block with 5% normal serum (from the same species as secondary antibody) for 30 minutes.

• Primary antibody: Apply diluted ADAL-1 antibody (1:100 to 1:500) and incubate at 4°C overnight or 1-2 hours at room temperature.

• Detection system: Use appropriate detection system (such as HRP-polymer) according to manufacturer's instructions.

• Counterstaining: Counterstain with hematoxylin, dehydrate, and mount.

Optimization of antibody dilution and antigen retrieval conditions is essential for specific staining and minimal background .

How can ADAL-1 antibody be integrated into multiplex immunoassay systems?

Integrating ADAL-1 antibody into multiplex immunoassay systems requires careful consideration of antibody compatibility and detection strategies. For fluorescence-based multiplex systems, ADAL-1 antibody can be directly labeled with fluorophores such as FITC, which has been validated for this antibody . When designing multiplex panels, researchers should select antibodies raised in different host species or use isotype-specific secondary antibodies to prevent cross-reactivity. For electrochemiluminescence-based platforms, researchers can adapt methodology similar to that described for other antibody detection systems using SULFO-TAG labeled detection reagents, such as Protein-A/G for broad species reactivity . To minimize background and enhance specificity in multiplex systems, optimal blocker-diluents should be employed, such as those identified in similar antibody detection systems (ChonBlock, Assay Diluent, or Blocker casein) .

What strategies can overcome common technical challenges when using ADAL-1 antibody?

Researchers frequently encounter technical challenges when working with ADAL-1 antibody. Here are methodological approaches to overcome common issues:

• High background signal:

  • Increase blocking time (up to 2 hours) with 5% BSA or 5% normal serum

  • Use optimized blocker-diluents that maximize signal-to-noise ratios

  • Implement a data transformation strategy involving target-coated and uncoated wells to normalize background signals

  • Increase washing steps (5-6 washes) with 0.1% Tween-20 in buffer

• Weak or no signal detection:

  • Optimize protein extraction methods to ensure proper exposure of epitopes

  • Test different antigen retrieval methods for IHC applications

  • Decrease antibody dilution (increase concentration)

  • Extend primary antibody incubation time

• Non-specific binding:

  • Employ more stringent washing procedures

  • Pre-adsorb the antibody with non-specific proteins

  • Use peptide competitors to confirm specificity

  • Implement matched isotype controls to verify signal specificity

• Cross-reactivity concerns:

  • Validate specificity using ADAL knockout/knockdown samples

  • Perform peptide competition assays with the immunizing peptide

  • Use species-specific detection systems when working across multiple species

How should researchers analyze and interpret quantitative data generated using ADAL-1 antibody?

When analyzing quantitative data from experiments using ADAL-1 antibody, researchers should follow these methodological principles:

• Standard curve preparation:

  • Generate a standard curve using recombinant ADAL protein or a surrogate specific antibody diluted in human serum at 1/100 dilution in appropriate buffers

  • Ensure the standard curve encompasses the expected range of ADAL in experimental samples

• Data normalization strategies:

  • Normalize signal responses using both ADAL-coated and uncoated wells to reduce inter-subject variability and increase distributional normality

  • Apply parametric statistical methods after confirming normal distribution of data

• Establishing valid detection thresholds:

  • Implement screening cut points based on statistical analysis of background responses

  • Calculate signal-to-noise ratios to determine meaningful detection limits

  • Apply appropriate outlier identification and management procedures

• Comparative analysis across experimental conditions:

  • Account for biological variation by including multiple biological replicates

  • Apply appropriate statistical tests (ANOVA, t-test) after confirming data meets assumptions

  • Consider fold-change values in addition to absolute measurements for biologically meaningful interpretation

• Validation of results:

  • Confirm findings using complementary detection methods

  • Include positive and negative controls in each experimental run

  • Verify consistency across technical replicates

What quality control measures should be implemented when working with ADAL-1 antibody?

Implementing rigorous quality control measures is essential when working with ADAL-1 antibody to ensure reliable and reproducible results. Researchers should:

• Validate antibody lot consistency:

  • Test each new lot against a reference standard

  • Compare staining patterns or signal intensities between lots

  • Document lot-specific working dilutions and conditions

• Include appropriate controls in each experiment:

  • Positive control (tissue/cells known to express ADAL)

  • Negative control (ADAL-negative samples or ADAL-knockout models)

  • Technical controls (secondary antibody only, isotype control)

  • Peptide competition controls (pre-incubation with immunizing peptide)

• Monitor antibody stability and storage conditions:

  • Store according to manufacturer recommendations (typically at -20°C)

  • Avoid repeated freeze-thaw cycles (aliquot upon receipt)

  • Track antibody performance over time to detect potential degradation

• Standardize experimental protocols:

  • Document detailed protocols including all parameters

  • Use consistent reagents and instruments across experiments

  • Implement regular calibration of detection instruments

• Employ statistical quality control:

  • Establish acceptance criteria for control samples

  • Monitor inter-assay and intra-assay coefficients of variation

  • Implement Levey-Jennings charts for longitudinal quality tracking

How can researchers troubleshoot inconsistent results between different batches of ADAL-1 antibody?

When facing inconsistent results between antibody batches, researchers should systematically:

• Perform side-by-side comparison testing:

  • Run parallel experiments with both old and new antibody batches

  • Use identical samples, conditions, and protocols

  • Quantify and document differences in signal intensity, specificity, or background

• Adjust working concentrations:

  • Titrate each new batch to determine optimal working dilution

  • Consider that different batches may require different dilution factors

  • Document batch-specific dilutions for future reference

• Modify incubation conditions:

  • Test different incubation times and temperatures

  • Examine if longer primary antibody incubation improves consistency

  • Optimize secondary antibody parameters independently

• Enhance blocking and washing procedures:

  • Test alternative blocking reagents to reduce background

  • Increase washing stringency to improve signal-to-noise ratio

  • Consider different buffer compositions to stabilize antibody-antigen interactions

• Implement epitope retrieval optimization:

  • For IHC applications, test different antigen retrieval methods

  • Adjust retrieval duration and temperature conditions

  • Consider dual retrieval approaches for challenging samples

What validation steps should be performed to confirm ADAL-1 antibody specificity?

To rigorously validate ADAL-1 antibody specificity, researchers should implement these methodological approaches:

• Genetic validation:

  • Test antibody on samples from ADAL knockout models

  • Examine samples with ADAL knockdown via siRNA/shRNA

  • Use CRISPR-Cas9 edited cell lines with ADAL modifications

• Peptide competition assays:

  • Pre-incubate antibody with increasing concentrations of immunizing peptide

  • Observe dose-dependent reduction in signal

  • Include irrelevant peptide controls to confirm specificity

• Orthogonal detection methods:

  • Compare antibody results with orthogonal techniques (mass spectrometry)

  • Correlate protein detection with mRNA expression data

  • Verify cellular/tissue distribution patterns match known biology

• Immunoprecipitation followed by mass spectrometry:

  • Perform IP using ADAL-1 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm ADAL protein as the predominant target

• Cross-reactivity assessment:

  • Test against closely related family members (other adenosine deaminases)

  • Evaluate performance across multiple species

  • Document any unexpected cross-reactivity patterns

How can ADAL-1 antibody be utilized in studying enzyme-substrate interactions?

ADAL-1 antibody offers valuable methodological approaches for investigating enzyme-substrate interactions of the adenosine deaminase-like protein. Researchers can:

• Implement co-immunoprecipitation studies:

  • Use ADAL-1 antibody to pull down ADAL protein complexes

  • Identify interaction partners through western blotting or mass spectrometry

  • Analyze how substrate binding affects complex formation

• Develop activity-based enzyme assays:

  • Employ ADAL-1 antibody to capture the enzyme from complex mixtures

  • Measure enzymatic activity on N6-methyl-AMP substrate

  • Analyze how antibody binding affects catalytic function

• Perform conformational change studies:

  • Use ADAL-1 antibody in combination with proteolytic fingerprinting

  • Detect substrate-induced conformational changes

  • Map regions protected from proteolysis upon substrate binding

• Analyze post-translational modifications:

  • Combine ADAL-1 antibody with phospho-specific or other PTM antibodies

  • Determine how PTMs affect substrate recognition and catalysis

  • Track dynamic modifications during enzyme-substrate interactions

• Conduct structure-function relationship studies:

  • Use epitope-specific antibodies to block particular domains

  • Correlate domain accessibility with enzymatic function

  • Map critical regions for substrate recognition and processing

What are the considerations for using ADAL-1 antibody in clinical research applications?

When incorporating ADAL-1 antibody into clinical research, investigators should address these methodological considerations:

• Assay validation for clinical samples:

  • Establish reproducibility across different patient cohorts

  • Develop standardized protocols suitable for clinical specimens

  • Determine reference ranges in healthy versus disease states

• Sample preparation optimization:

  • Evaluate compatibility with various clinical sample types (serum, plasma, tissue)

  • Standardize collection, processing, and storage procedures

  • Assess potential interfering substances in clinical specimens

• Regulatory compliance:

  • Document validation parameters according to regulatory guidelines

  • Consider FDA/EMA requirements if developing diagnostic applications

  • Implement quality control systems appropriate for clinical research

• Clinical correlation studies:

  • Design studies to correlate ADAL expression/activity with clinical outcomes

  • Incorporate appropriate disease controls and matched healthy samples

  • Consider longitudinal sampling to track changes over disease course

• Data interpretation in clinical context:

  • Establish clinical decision thresholds and reference ranges

  • Analyze results in context of other clinical parameters

  • Implement blinded assessment procedures to minimize bias

How can ADAL-1 antibody contribute to understanding the role of ADAL in enzymatic pathways?

ADAL-1 antibody provides powerful tools for elucidating ADAL's role in enzymatic pathways through these methodological approaches:

• Pathway analysis through protein complex identification:

  • Use ADAL-1 antibody in proximity ligation assays to detect in situ interactions

  • Identify pathway components through co-immunoprecipitation followed by proteomics

  • Map dynamic changes in protein interactions under different cellular conditions

• Subcellular localization studies:

  • Implement immunofluorescence with ADAL-1 antibody (FITC-conjugated or with appropriate secondary)

  • Track subcellular distribution changes during pathway activation

  • Correlate localization patterns with enzymatic activity

• Functional inhibition experiments:

  • Use ADAL-1 antibody to block specific domains

  • Analyze pathway perturbations following inhibition

  • Correlate functional outcomes with biochemical changes

• Temporal dynamics investigations:

  • Apply ADAL-1 antibody in time-course experiments

  • Track expression and activity changes following pathway stimulation

  • Identify regulatory feedback mechanisms

• Cross-talk analysis with related enzymatic systems:

  • Compare ADAL activity with other adenosine deaminases

  • Investigate compensatory mechanisms upon ADAL inhibition

  • Analyze effects of pathway modulators on ADAL expression and function

How can ADAL-1 antibody be integrated with emerging single-cell analysis technologies?

Integration of ADAL-1 antibody with single-cell technologies offers powerful new research capabilities. Methodologically, researchers should:

• Optimize antibody parameters for single-cell applications:

  • Test different fixation and permeabilization protocols compatible with single-cell retention

  • Determine optimal concentrations that maximize signal while minimizing background

  • Evaluate compatibility with multiplexed antibody panels

• Adapt for mass cytometry (CyTOF) applications:

  • Conjugate ADAL-1 antibody with rare earth metals

  • Validate metal-conjugated antibody performance against standard methods

  • Incorporate into multiplexed panels with minimal signal overlap

• Implement in spatial transcriptomics platforms:

  • Combine ADAL-1 antibody staining with spatial transcriptomics methods

  • Correlate protein expression with transcript localization

  • Develop computational approaches to integrate protein and RNA data

• Apply to microfluidic-based single-cell proteomics:

  • Adapt ADAL-1 antibody for microfluidic antibody capture systems

  • Validate sensitivity at single-cell resolution

  • Develop quantification standards for absolute protein measurement

• Incorporate into live-cell imaging systems:

  • Use fluorescently labeled ADAL-1 antibody fragments for live-cell applications

  • Monitor dynamic changes in protein localization and abundance

  • Correlate with functional readouts in real-time

What are the considerations for using ADAL-1 antibody in conjunction with CRISPR-based gene editing systems?

When combining ADAL-1 antibody with CRISPR-based technologies, researchers should methodologically address:

• Validation of gene editing efficiency:

  • Use ADAL-1 antibody to quantify protein reduction following CRISPR knockout

  • Establish quantitative relationships between genomic modification and protein levels

  • Compare temporal dynamics of mRNA versus protein reduction

• Phenotypic characterization:

  • Apply ADAL-1 antibody to analyze cellular phenotypes in edited cells

  • Track protein expression in clonal populations versus mixed edited pools

  • Correlate protein levels with functional readouts

• Domain-specific functional analysis:

  • Design CRISPR strategies to target specific protein domains

  • Use ADAL-1 antibody to verify truncated protein expression

  • Analyze domain-specific functions through antibody detection of modified proteins

• Rescue experiments:

  • Confirm specificity of CRISPR effects through rescue expression

  • Use ADAL-1 antibody to verify appropriate expression of rescue constructs

  • Quantify restoration of protein levels in correlation with functional rescue

• Off-target effect assessment:

  • Examine potential alterations in related protein family members

  • Implement proteome-wide analysis in conjunction with targeted antibody detection

  • Correlate phenotypic changes with specific protein alterations

How will advances in antibody engineering impact future applications of ADAL-1 antibody?

Emerging antibody engineering technologies will expand ADAL-1 antibody capabilities through:

• Development of site-specific conjugation methods:

  • Engineer ADAL-1 antibody with precisely positioned conjugation sites

  • Improve orientation control for surface immobilization applications

  • Enhance performance in biosensor and diagnostic platforms

• Antibody fragment adaptation:

  • Generate Fab, scFv, or nanobody formats of ADAL-1 antibody

  • Improve tissue penetration for in vivo applications

  • Reduce non-specific binding while maintaining specificity

• Bispecific antibody development:

  • Create bispecific formats targeting ADAL and interacting proteins

  • Enable simultaneous detection of pathway components

  • Facilitate pull-down of protein complexes in their native state

• Incorporation of environmentally responsive elements:

  • Develop pH-sensitive or protease-activated ADAL-1 antibody variants

  • Enable conditional binding in specific cellular compartments

  • Create activity-based sensing capabilities

• Integration with synthetic biology approaches:

  • Combine ADAL-1 antibody with engineered cellular circuits

  • Develop antibody-based feedback control systems

  • Create synthetic regulatory networks responsive to ADAL protein levels or activity